INBXInhibrx Biosciences, Inc.

Health Care

Increase (Decrease) in Accounts Receivable revised down 9.3% for Q1 2025

This is the 7th largest revision in INBX's history.

Increase (Decrease) in Accounts Receivable

Q1 2025

Notable restatement

As reported

-$183K

Restated

-$200K

-9.3%

Verify against SEC filingsShow

As reported-$183K

Restated-$200K

AccountsReceivableChange · reported 2 times · point-in-time, survivorship-free. Every figure traces to its filing above.

Track this the moment it happens

Get an alert the next time INBX — or any company on your watchlist — restates a number. Every alert lands with the diff and its source filing.